Über

People who are 65 and older can be at greater risk of some side effects from Natesto. Ask your pharmacist or another health care provider before using any other products in your nose, such as over-the-counter (OTC) nasal sprays. Natesto can cause changes in the lipid (fat) levels in your blood, including cholesterol.
Although it is not known how much testosterone transfers into human milk, Natesto is contraindicated in nursing women because of the potential for serious adverse reactions in nursing infants. Advise patients to report any nasal symptoms or signs to their health care professional. Gynecomastia may develop and may persist in patients being treated with androgens, including Natesto, for hypogonadism.see ADVERSE REACTIONS. There have been postmarketing reports of venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), in patients using testosterone products such as Natesto.
These side effects are usually mild but can sometimes be severe. While less common, the most serious side effects of Natesto are described below, along with what to do if they happen. Contact your health care provider if you think you are having a side effect of a medicine.. Patients with the lowest endogenous testosterone levels received maximum exposure impact from each TNG dose. The maximal concentration of TT was nearly identical across all cohorts at days 30 and 90, whereas the average concentration over 24 hours had a slight positive dependence relative to predose levels. Prestudy and predose endogenous testosterone concentrations correlated. The same dose of Natesto is effective in most men regardless of baseline T levels.2|Long term clinical safety trials have not been conducted to assess the cardiovascular outcomes of testosterone replacement therapy in men. The primary endpoint was the percentage of patients with an average serum total testosterone concentration (Cavg) within the normal range (300 to 1050 ng/dL) on Day 90. Eligible patients were 18 years of age and older (mean age 54 years) and had morning serum total testosterone concentrations less than 300 ng/dL. After 90 days of treatment, the mean DHT/testosterone ratio was 0.09 which was within the normal range.|Natesto contains testosterone, a Schedule III controlled substance in the Controlled Substances Act. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus. Exposure of a fetus to androgens may result in varying degrees of virilization. Drug interaction potential with other nasally administered drugs other than oxymetazoline has not been studied.|There is suggestive evidence that injection of testosterone into some strains of female mice increases their susceptibility to hepatoma. Advise the patient to read the FDA-approved patient labeling (PATIENT INFORMATION). Free thyroid hormone concentrations remain unchanged; however, and there is no clinical evidence of thyroid dysfunction. Androgens, including Natesto, may promote retention of sodium and water. If testosterone abuse is suspected, check serum testosterone concentrations to ensure they are within therapeutic range. If a venous thromboembolic event is suspected, discontinue treatment with Natesto and initiate appropriate workup and management see ADVERSE REACTIONS.|Due to lack of controlled studies in women and potential virilizing effects, Natesto is not indicated for use in women. Anabolic androgenic steroid abuse can lead to serious cardiovascular and psychiatric adverse reactions see Drug Abuse And Dependence. Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. Evaluate patients who report symptoms of pain, edema, warmth and erythema in the lower extremity for (DVT) and those who present with acute shortness of breath for PE. Patients should be instructed to report any nasal symptoms or signs to their health care professional. The percentages of patients with Cmax greater than 1500 ng/dL and between 1800 and 2500 ng/dL were 15.9% and 1.4%, respectively.|The drug interaction potential between Natesto and nasally administered drugs other than sympathomimetic decongestants is unknown. If the patient gets Natesto gel on their hands, it is recommended that they wash their hands with warm water and soap. Patients should be instructed to completely depress the pump 1 time in each nostril to receive the total dose.}
Unlike testosterone ester and ether prodrugs however, these prohormones are only weakly androgenic/anabolic. However, estradiol exerts negative feedback on the hypothalamic–pituitary–gonadal axis and, for this reason, prevention of its formation can reduce this feedback and disinhibit gonadal production of testosterone, which in turn can increase levels of endogenous testosterone. However, these drugs do this via prevention of the conversion of testosterone into its more potent metabolite dihydrotestosterone (DHT), and this results in dramatically reduced circulating levels of DHT (which circulates at much lower relative concentrations). 5α-Reductase inhibitors like finasteride and dutasteride can slightly increase circulating levels of testosterone by inhibiting its metabolism.

Weiblich